Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: Long-term outcome of 61 patients from a single institution

References

• Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Dermirer T, Dini G, Einsele H, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439–449
   PubMed Web of Science ®Google Scholar
• Linch D C, Winfield D, Goldstone A H, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, Sieber M, Carella M, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071
   PubMed Web of Science ®Google Scholar
• Reece D E, Connors J M, Spinelli J, Barnett M J, Fairey R N, Klingermann H, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193–1199
   PubMed Web of Science ®Google Scholar
• Nademanee A, O'Donnell M R, Snyder D S, Schmidt G, Parker P, Stein A, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381–1390
   PubMed Web of Science ®Google Scholar
• Yuen A R, Rosenberg S A, Hoppe R T, Halpern J, Horning S. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814–822
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan A K, Linch D C, Yuklea S, Taghipour G, Pearce R, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137–1145
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Loberiza F R, Zhang M J, Armitage J O, Ballen K K, Bashey A, et al. Autotransplantation for Hodgkin's disease in first relapse or second remission: a report from the Autologous Blood and Marrow Transplantation Registry (ABMTR). Bone Marrow Transplant 2001; 27: 387–396
   PubMed Web of Science ®Google Scholar
• Sureda A, Constans M, Irondo A, Arranz R, Caballero M D, Vidal M J, et al. Prognostic factors affecting long-term outcome after stem-cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625–633
   PubMed Web of Science ®Google Scholar
• Crump M, Smith A M, Brandwein J, Couture F, Sherret H, Sutton D M, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993; 11: 704
   PubMed Web of Science ®Google Scholar
• Rapoport A P, Rowe J M, Kouides P A, Duerst R A, Abboud C N, Liesveld J L, et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351–2361
   PubMed Web of Science ®Google Scholar
• Josting A, Katay I, Rueffer U, Winter S, Tesh H, Engert A, et al. Favourable outcome of patients relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell transplantation at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 1998; 9: 289–295
   PubMed Web of Science ®Google Scholar
• Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96: 1280–1286
   PubMed Web of Science ®Google Scholar
• Popat U, Hosing C, Saliba R M, Anderlini P, van Besien K, Przepiorka D, et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 1015–1023
   PubMed Web of Science ®Google Scholar
• Bierman P J, Lynch J C, Bociek R G, Whalen V L, Kessinger A, Vose J M, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002; 13: 1370–1377
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta J J, García-Conde J, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395–1404
   PubMed Web of Science ®Google Scholar
• Sweetenham J, Carella A, Taghipour G, Cunningham D, Marcus R, Della Volpe A, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999; 17: 3101–3109
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Rowlings P A, Zhang M J, Vose J M, Armitage J, Bierman P, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplantation Registry (ABMTR). J Clin Oncol 1999; 17: 534–545
   PubMed Web of Science ®Google Scholar
• Constans M, Sureda A, Terol M J, Arranz R, Caballero M D, Irondo A, et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol 2003; 14: 745–751
   PubMed Web of Science ®Google Scholar
• Fermé C, Mournier N, Diviné M, Brice P, Stamatoullas A, Reman O, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467–475
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Eng J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Horning S J, Chao N J, Negrin R S, Hoppe R, Long G, Hu W, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–813
   PubMed Web of Science ®Google Scholar
• Brenot-Rossi I, Bouabdallah R, Di Stefano D, Bardou V J, Stoppa A M, Camerlo J, et al. Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy. Eur J Nucl Med 2001; 28: 1482–1488
   PubMedGoogle Scholar
• Delcambre C, Reman O, Henry-Amar M, Peny Am, Macro M, Cheze S, et al. Clinical relevance of 67-gallium scintigraphy in lymphoma before and after chemotherapy. Eur J Nucl Med 2000; 27: 176–184
   PubMedGoogle Scholar